Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
How Has the Anti-D Immunoglobulin Market Performed Historically, and What Are Its Future Growth Projections?
The anti-D immunoglobulin market size has grown strongly in recent years. It will grow from $2.42 billion in 2024 to $2.59 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to increasing awareness of rhesus incompatibility risks, expanding national immunization programs, implementation of maternal and neonatal health policies, rising global birth rates, and growth in blood transfusion procedures.
The anti-D immunoglobulin market size is expected to see strong growth in the next few years. It will grow to $3.34 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to rising demand for antenatal and perinatal care, growing emphasis on maternal health in low- and middle-income countries, increasing healthcare infrastructure investments, expansion of universal health coverage programs, and regulatory support for immunoglobulin therapies. Major trends in the forecast period include advancements in plasma fractionation technology, development of recombinant antibody alternatives, increasing automation in immunoglobulin production, adoption of high-purity formulation techniques, and integration of cold chain monitoring systems.
Get your free report sample today:
What Are the Essential Drivers Propelling the Anti-D Immunoglobulin Market Forward?
The high birth rates are expected to propel the growth of the anti-D immunoglobulin market going forward. Birth rates represent the number of live births recorded annually for every 1,000 people in a population. Birth rates are increasing due to insufficient access to education and family planning services, resulting in higher fertility and larger families. Anti-D immunoglobulin helps birth rates by preventing Rh incompatibility in pregnancy, which reduces the risk of hemolytic disease in newborns and supports healthier outcomes in future pregnancies. For instance, in April 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, there were 3,622,673 recorded births in 2024, reflecting a 1% increase from the previous year. Therefore, the high birth rates are driving the growth of the anti-D immunoglobulin market.
The expanding healthcare infrastructure is expected to propel the growth of the anti-D immunoglobulin market going forward. Healthcare infrastructure refers to the system of facilities, equipment, workforce, and support mechanisms essential for delivering healthcare services within a population. Healthcare infrastructure is expanding as a result of the growing global population, which drives higher demand for medical care and necessitates the development of more hospitals, clinics, and related resources. Healthcare infrastructure expansion enhances access to maternal healthcare, enabling better screening and timely use of anti-D immunoglobulin to prevent hemolytic disease in newborns. For instance, in May 2023, according to the Department of Health and Social Care, a UK-based government department, the government announced plans to allocate more than $27 billion (£20 billion) toward building new hospital facilities. As part of the New Hospital Programme, two hospitals are already finished, five are currently being built, and over 20 are set to be underway or completed by the end of the following year. Therefore, the expanding healthcare infrastructure is driving the growth of the anti-D immunoglobulin market.
What Are the Primary Market Segments in the Anti-D Immunoglobulin Market?
The anti-d immunoglobulin market covered in this report is segmented –
1) By Product Type: Intramuscular Anti-D Immunoglobulin, Intravenous Anti-D Immunoglobulin
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel
3) By Application: Hemolytic Disease Of The Newborn, Immune Thrombocytopenic Purpura, Antenatal And Postnatal Prophylaxis, Other Applications
4) By End-User: Hospitals, Clinics, Blood Banks, Research Laboratories
Subsegments:
1) By Intramuscular Anti-D Immunoglobulin: Standard Dose, High Dose, Pre-Filled Syringes, Vials
2) By Intravenous Anti-D Immunoglobulin: Lyophilized Powder, Liquid Formulation, Single-Use Vials, Multi-Dose Vials
What Are the Key Industry Trends Driving Growth in the Anti-D Immunoglobulin Market?
Major companies operating in the anti-D immunoglobulin market are focusing on developing innovative solutions such as recombinant anti-D immunoglobulin to expand access to safe and reliable prophylaxis for Rh-negative pregnant individuals and improve maternal outcomes. A recombinant anti-D immunoglobulin is a lab-engineered monoclonal antibody designed to prevent Rh incompatibility in Rh-negative individuals, offering an alternative to plasma-derived anti-D therapies with enhanced consistency, safety, and scalability. For instance, in January 2022, Bharat Serums and Vaccines (BSV), an India-based biopharmaceutical company, launched the world’s first marketed recombinant anti-Rho (D) immunoglobulin. The product introduces a scientifically advanced approach to Rh prophylaxis by utilizing recombinant technology, which enhances product reliability and minimizes variability associated with plasma-derived alternatives. Its availability is particularly significant in regions with high numbers of Rh-negative pregnancies, where it can improve preventive care and reduce the risk of hemolytic disease in newborns.
Who Are the Top Performers and Innovators in the Anti-D Immunoglobulin Market?
Major companies operating in the anti-d immunoglobulin market are Merck Group, Bayer AG, CSL Behring, Baxter International Inc., Intas Pharmaceuticals Ltd., Octapharma AG, Zydus Lifesciences Limited, Emergent BioSolutions Inc., Kedrion Biopharma Inc., Biotest AG, Sanquin, Taj Pharmaceuticals Limited, Kamada Pharmaceuticals, Bharat Serums and Vaccines Limited, Saol Therapeutics Inc., Aetos Pharma Private Limited, Avin Darou, PV Pharma Healthcare Pvt. Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Ocean Pharmacoat Pvt. Ltd.
Get the detailed anti-d immunoglobulin market report today
Which Regional Markets Are Likely to See the Most Significant Expansion in the Coming Years?
North America was the largest region in the anti-D immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-d immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment